Business context and reporting period
Entity note: The request identifies Canton Strategic Holdings, Inc., but the supplied 10-Q is for Tharimmune, Inc. (Nasdaq: THAR). This summary reflects the filing provided. It covers the three months ended March 31, 2024; the report was signed May 9, 2024.
Tharimmune is a clinical-stage biotechnology company with no commercial revenue. Its programs include TH104 and TH103, as well as early-stage immuno-oncology candidates TH3215, TH0059 and TH1940.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.03 million | $1.05 million |
| General and administrative expense | $1.32 million | $1.67 million |
| Total operating expenses | $2.35 million | $2.71 million |
| Net loss | $2.26 million | $2.69 million |
| Net loss per share, basic and diluted | $0.19 | $5.84 |
| Operating cash used | $2.83 million | $3.46 million |
| Cash and current assets, March 31, 2024 | $8.43 million / $8.89 million | Cash: $10.94 million at December 31, 2023 |
| Current liabilities, March 31, 2024 | $1.84 million | $1.82 million at December 31, 2023 |
No gross profit or operating margin is reported because the company had no revenue. Interest income was $95,894 and interest expense was $4,700. The company reported no long-term debt; current liabilities included a $317,119 insurance premium financing liability. Stockholders’ equity was $7.05 million at quarter-end.
Material changes versus the prior comparable period
- Net loss narrowed by $432,179, or about 16%, and total operating expenses declined by $367,095, or about 14%.
- R&D expense decreased about 2%; lower preclinical and stock-based compensation costs were partly offset by TH104 clinical trial costs and licensing fees.
- G&A expense declined about 21%, primarily due to lower investor relations, legal, insurance and stock-based compensation costs, partly offset by increased personnel expense following the COO’s appointment.
- Interest income rose to $95,894 from $32,248, which management attributed primarily to cash raised in the November 2023 offering.
- Cash used in operations improved by about $640,000 year over year. Cash nevertheless declined $2.51 million during Q1 2024, after $317,119 of net cash from insurance premium financing.
- The company issued 50,000 shares for services in January 2024, valued at $20,550. Shares outstanding were 11,789,676 as of May 8, 2024.
Outlook, risks and unusual items
- Going concern and funding: Management says substantial additional funding is needed and that conditions raise substantial doubt about the company’s ability to continue as a going concern for at least one year after issuance of the financial statements. Funding could come from equity or debt, partnerships, grants or other arrangements, but availability and terms are uncertain. A funding shortfall could delay or terminate development activities.
- Development outlook: Management expects R&D and G&A expenses to increase as programs advance and the company supports development. The filing gives no quantified earnings, cash-flow or revenue guidance.
- TH104 study: A Phase 1 pharmacokinetic bridging study was completed, with 19 subjects completing the study. Preliminary safety findings were described as comparable to the reference formulation; reported adverse events were mild, with no serious adverse events or deaths. Full data was expected in Q2 2024.
- Pipeline timing: The financial-statement note says TH3215, TH0059 and TH1940 were anticipated to enter IND-enabling studies in 2024, while MD&A states 2025. The filing therefore contains inconsistent timing statements.
- License obligations: The Avior agreement includes $24.25 million in aggregate development milestone payments, plus sales milestones and royalties if applicable. The company paid Avior $150,000 in milestone fees in Q1. Other collaboration agreements also provide for milestone payments and royalties.
- Contingencies and controls: The company reported no material legal proceedings or material changes to previously disclosed risk factors. Management concluded disclosure controls were effective as of March 31, 2024; no significant change in internal control was reported.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Tharimmune, Inc., not Canton Strategic Holdings, Inc.
- Assess cash runway against the reported $2.83 million quarterly operating cash use and management’s explicit going-concern warning; the filing does not provide a clear runway estimate.
- Check whether TH104 full Phase 1 results were subsequently reported and how they affect development plans.
- Clarify the IND-enabling timeline for TH3215, TH0059 and TH1940, given the 2024 versus 2025 statements.
- Review potential future dilution and financing needs alongside the outstanding options and warrants and the company’s license-related milestone obligations.